Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemosensitivity-guided adjuvant chemotherapy versus empiric adjuvant chemotherapy after gastric cancer resection
ChiCTR-TRC-11001439Phase 2Completed
- Sponsor
- Nantong Cancer Hospital
- Start
- Aug 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epirubicin, oxaliplatin, fluorouracil, docetaxel, cisplatin and 2 more in gastric cancer (GC) (2 arms), sponsored by Nantong Cancer Hospital. Primary endpoints: 3-year disease-free survival and Adverse reactions. Started Aug 2011; status: completed.
02
Drugs
epirubicinoxaliplatinfluorouracildocetaxelcisplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001439.